{
  "trial_id": "NCT01790438",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, duration of type 2 diabetes, baseline HbA1c, body mass index (BMI), fasting blood glucose, blood pressure, lipid profile (total cholesterol, LDL, HDL, triglycerides), renal function (serum creatinine), liver function tests (ALT, AST), history of cardiovascular disease, use of oral antihyperglycemic medications (OAMs), smoking status, alcohol consumption, physical activity level, dietary habits.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Body Mass Index (BMI)",
          "body mass index (BMI)"
        ],
        [
          "Duration of Diabetes",
          "duration of type 2 diabetes"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "baseline HbA1c",
        "fasting blood glucose",
        "blood pressure",
        "lipid profile (total cholesterol, LDL, HDL, triglycerides)",
        "renal function (serum creatinine)",
        "liver function tests (ALT, AST)",
        "history of cardiovascular disease",
        "use of oral antihyperglycemic medications (OAMs)",
        "smoking status",
        "alcohol consumption",
        "physical activity level",
        "dietary habits"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Total Cholesterol, Triglycerides, Serum Creatinine, Fasting Plasma Glucose, Use of Oral Antihyperglycemic Medications (OAM),",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Duration of Diabetes",
          "Duration of Diabetes"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Baseline HbA1c",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Total Cholesterol",
        "Triglycerides",
        "Serum Creatinine",
        "Fasting Plasma Glucose",
        "Use of Oral Antihyperglycemic Medications (OAM)"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Duration, Body Mass Index, HbA1c, Fasting Plasma Glucose, Systolic Blood Pressure, Diastolic Blood Pressure, Total Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol, Use of Oral Antihyperglycemic Medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Duration of Diabetes",
          "Diabetes Duration"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "HbA1c",
        "Fasting Plasma Glucose",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Total Cholesterol",
        "Triglycerides",
        "HDL Cholesterol",
        "LDL Cholesterol",
        "Use of Oral Antihyperglycemic Medications."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes, hemoglobin A1c (HbA1c) at screening, fasting plasma glucose at screening, systolic and diastolic blood pressure, heart rate, waist circumference, lipid profiles (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides), smoking status, medical history (including cardiac disease, renal disease, hepatic disease, cancer), concomitant medications, oral antihyperglycemic medications (OAMs) used prior to screening.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Body Mass Index (BMI)",
          "body mass index (BMI)"
        ],
        [
          "Duration of Diabetes",
          "duration of type 2 diabetes"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "hemoglobin A1c (HbA1c) at screening",
        "fasting plasma glucose at screening",
        "systolic and diastolic blood pressure",
        "heart rate",
        "waist circumference",
        "lipid profiles (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides)",
        "smoking status",
        "medical history (including cardiac disease, renal disease, hepatic disease, cancer)",
        "concomitant medications",
        "oral antihyperglycemic medications (OAMs) used prior to screening."
      ]
    }
  }
}